Table 3.
Summary of peer-reviewed literature reporting megaprosthesis survivorship
| Study | Year | Number of patients | Site | Prosthesis* | Implant survival (%) | Followup (years) |
|---|---|---|---|---|---|---|
| Unwin et al. [31] | 1993 | 218 | Distal femur | Stanmore | 65 | 10 |
| Langlais et al. [15] | 2006 | 26 | Distal femur | GUEPAR® II or custom press-fit cemented | 92 | 12.5 |
| Myers et al. [20] | 2007 | 332 | Distal femur | Stanmore | 67 | 10 |
| Zimel et al. [33] | 2009 | 47 | Distal femur | Howmedica 39 OSS™ 8 | 36 | 10 |
| Farfalli et al. [9] | 2009 | 50 | Distal femur | OSS™ uncemented | 71 | 10 |
| Shehadeh et al. [27] | 2010 | 101 | Distal femur | MSRS™ | 70 | 10 |
| Bergin et al. [3] | 2012 | 93 | Distal femur | MRS™/GMRS™ | 73 | 10 |
| Tan et al. [28] | 2012 | 78 | Distal femur | Custom | 71 | 10 |
| Roberts et al. [26] | 1991 | 135 | Distal femur | Stanmore | 72 | 5 |
| Horowitz et al. [11] | 1993 | 61 | Distal femur | Burstein-Lane® | 78 | 5 |
| Kawai et al. [12] | 1999 | 25 | Distal femur | Finn® | 88 | 5 |
| Griffin et al. [10] | 2005 | 74 | Distal femur | KMFTR™ uncemented | 70 | 14 |
| Bruns et al. [8] | 2007 | 13 | Distal femur | MUTARS® | 87 | 7 |
| Kinkel et al. [13] | 2010 | 49 | Distal femur | MUTARS® | 57 | 5 |
| Matsumine et al. [17] | 2011 | 69 | Distal femur | Kyocera | 85 | 5 |
| Ritschl et al. [25] | 1992 | 206 | Mixed | KMFTR™ | 73 | 10 |
| Unwin et al. [31] | 1993 | 218 | Mixed | Stanmore | 65 | 10 |
| Unwin et al. [30] | 1996 | 1001 | Mixed | Stanmore | 67.4 | 10 |
| Mascard et al. [16] | 1998 | 90 | Mixed | GUEPAR® | 60 | 10 |
| Mittermayer et al. [18] | 2001 | 41 | Mixed | KMFTR™ | 53 | 11 |
| Plötz et al. [24] | 2002 | 64 | Mixed | Custom | 25 | 10 |
| Bickels et al. [6]† | 2002 | 110 | Mixed | MSRS™ | 88 | 10 |
| Biau et al. [5] | 2006 | 56 | Mixed | Custom | 50 | 11 |
| Morgan et al. [19] | 2006 | 105 | Mixed | HMRS™ | 59 | 10 |
| Current study | 2012 | 82 | Distal femur | Compress® | 80 | 10 |
* Prostheses include Stanmore (Stanmore Implants Worldwide Ltd, Elstree, UK); GUEPAR® II (Stryker France, Lyon, France); OSS™ = Orthopaedic Salvage System (Biomet Inc, Warsaw, IN, USA); MSRS™ = Modular Segmental Reconstruction System (Stryker Howmedica, Mahwah, NJ, USA); MRS™/GMRS™ = Modular Replacement System/Global Modular Replacement System stems (Stryker Howmedica); Burstein-Lane® implant (Biomet Inc, Warsaw, IN, USA); Finn® (Biomet Inc); KMFTR™ = Kotz Modular Femur Tibia Reconstruction System (Howmedica, Rutherford, NJ, USA); MUTARS® = Modular Universal Tumour And Revision System (Implantcast GmbH, Buxtehude, Germany); Kyocera (Kyocera Medical Corp, Osaka, Japan); HMRS™ = Howmedica Modular Replacement System (Howmedica); †patients in this study were also included in the analysis by Shehadeh et al. [27].